Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Glenmark offloads...

    Glenmark offloads Indian gynaecology business for Rs 115 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-01-22T11:39:34+05:30  |  Updated On 22 Jan 2020 1:02 PM IST
    Glenmark offloads Indian gynaecology business for Rs 115 crore

    New Delhi: In an attempt to drag down the financial burden, drug giant Glenmark Pharmaceuticals Limited (Glenmark) recently sold off its gynaecology business in India and Nepal for Rs 115 crore (about $16.2 million) in cash. The gynaecology business portfolio has been acquired by private equity firm True North backed Integrace Pharma and includes brands like Dubagest, Mumfer, Fenza and Milical.

    The drugs, Dubagest is used to correct menstrual disorders caused due to a deficiency of this hormone in the body while Mumfer and Fenza are indicated to treat anaemia caused by abnormal heavy bleeding during menstrual periods (menorrhagia), pregnancy, or kidney problems; and fungal infections of the vagina (vulvovaginal candidiasis) respectively.

    Currently, the brands Dubagest, Mumfer and Fenza have sales of Rs 60 crore and are growing by 15%. However, the gynaecology business accounts for less than 1 per cent of Glenmark's total revenue.

    "The turnover of the Gynaecology business in India & Nepal for the year ended March 31, 2019, was less than 1% of the turnover of Glenmark Pharma on stand-alone basis," Glenmark said in a filing.

    Despite investing in the Research and Development (RnD) and the United States market the debt on the company has inflated, thereby, prompting the firm to trim down the burden via divestments.

    Prior to this, in 2018 Glenmark had entered into a collaboration with private equity firm True North for its orthopaedic and pain management business for India and Nepal market. Under this collaboration, Glenmark's orthopaedic and pain management business was valued at Rs 635 crore and was to be transferred to a new entity namely Integrace Pharma, incorporated by True North.

    Also Read: Glenmark Inks Pact With Private Equity Firm True North

    The country's gynaecology segment is estimated at Rs 12,500 crore and has been growing faster than the broader Indian pharmaceutical market. Glenmark's latest transaction which is likely to be completed by the end of March 2020 will stimulate growth for the Gynaecology business in the new entity.

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok